[en] PURPOSE: Piroxicam is a poorly soluble NSAID, whose solubility is enhanced when included into beta-cyclodextrin. The preparation of a piroxicam-beta-cyclodextrin inclusion compound using supercritical CO2 was investigated. METHODS: The solubility and the stability of piroxicam in supercritical CO2 were determined. Then, the influence of the temperature, the pressure and the time of exposure on the inclusion rate was studied. RESULTS: The solubility of piroxicam varied over a wide range depending on the temperature and pressure (from 0.006 to 1.500 mg/g of CO2). The temperature and the time of exposure had a great influence on the inclusion yield, while pressure did not and a complete inclusion was achieved by keeping a physical mixture of piroxicam and beta-cyclodextrin (1:2.5 mol/mol) for 6 hours at 150 degrees C and 15 MPa of CO2. This complex was characterized by Differential Scanning Calorimetry, differential solubility and Fourier Transform Infrared Spectrometry. CONCLUSIONS: Supercritical carbon dioxide may prove to be a novel useful complexation method of drugs into beta-cyclodextrin.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Van Hees, Thierry ; Université de Liège - ULiège > Département de pharmacie > Pharmacie clinique
Piel, Géraldine ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique et magistrale
Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Otte, Xavier
Thunus, Léopold ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Delattre, Luc ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Language :
English
Title :
Application of Supercritical Carbon Dioxide for the Preparation of a Piroxicam-Beta-Cyclodextrin Inclusion Compound
Publication date :
December 1999
Journal title :
Pharmaceutical Research
ISSN :
0724-8741
eISSN :
1573-904X
Publisher :
Kluwer Academic/Plenum Publishers, New York, United States - New York
L. Lasagna. Macrocyclic molecules and their pharmacological applications. Eur. J. Rheumatol. Inflamm. 12:3-5 (1993).
K-H Frömming and J. Szejtli. Cyclodextrin in Pharmacy, Kluwers Academic Publishers, Dordrecht, 1994.
R. Gallagher, C. Ball, D. Gatehouse, P. Gates, M. Lobell, and P. Derrick. Cyclodextrin-piroxicam inclusion complexes: analyses by mass spectrometry and molecular modelling. Int. J. Mass Spectro. Ion Proc. 165/166:523-531 (1997).
X. Deroubaix, A. Stockis, A. M. Allemon, E. Lebacq, D. Acerbi, and P. Ventura. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions. Eur. J. Clin. Pharmacol. 47:531-536 (1995).
B. Woodcock, D. Acerbi, P. Merz, S. Rietbrock, and N. Rietbrock N. Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J. Rheumatol. Inflamm. 12:12-28 (1993).
S-Y Lin and Y-H Kao. Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Int. J. Pharm. 56:249-259 (1989).
M. Kurozumi, N. Nambu, and T. Nagai. Inclusion compounds of non-steroidal anti-inflammatory and other slightly water soluble drugs with α- and β-cyclodextrins in powdered form. Chem. Pharm. Bull. 23:3062-3068 (1975).
J-H Kim, T. Paxton, and D. Tomasko. Microencapsulation of naproxen using rapid expansion of supercritical solutions. Biotechnol. Prog. 12:650-661 (1996).
M. Kamihira, T. Asai, Y. Yamagata, M. Taniguchi, and T. Kobayashi. Formation of inclusion complexes between cyclodextrins and aromatic compounds under pressurized carbon dioxide. J. Ferment. Bioeng. 69:350-353 (1990).
F. Giordano, M. Rillosi, G. P. Bettinetti, A. Gazzaniga, M. Majewski, and M. Perrut. Interaction of supercritical fluids with drug/cyclodextrin inclusion compounds and physical mixtures. Proc. 8th Int. Symposium on Cyclodextrins, 193-196 (1996).
D. Acerbi, G. Bovis, F. Carli, M. Pasini, L. Pavesi, and T. Peveri. Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds. Drug Invest. 2 (suppl. 4):29-36 (1990).
J. Bleich, P. Kleinebudde, and B. W. Müller. Influence of gas density and pressure on microparticles produced with the ASES process. Int. J. Pharm. 106:77-84 (1994).
D. Miller and S. Hawthorne. Determination of solubilities of organic solutes in supercritical CO2 by on-line flame ionization detection. Anal. Chem. 67:273-279 (1995).
K. Bartle, A. Clifford, S. Jafar, and G. Shilstone. Solubilities of solids and liquids of low volatility in supercritical carbon dioxide. J. Phys. Ref. Data 20(4):713-756 (1991).
S. Mitra and N. Wilson. An empirical method to predict solubility in supercritical fluids. J. Chromatogr. Sci. 29:305-309 (1991).
S. Macnaughton, I. Kikic, N. Foster, P. Alessi, A. Cortesi, and I. Colombo. Solubility of anti-inflammatory drugs in supercritical carbon dioxide. J. Chem. Eng. Data 41:1083-1086 (1996)
M. McHugh and V. Krukonis. Supercritical fluid extraction: principles and practice, Butterworths, London, 1986.
Pharmeuropa 9:387-391 (1997).
E. Redenti, T. Peveri, M. Zanol, P. Ventura, G. Gnappi, and A. Montenero. A study on the differentiation between amorphous piroxicam:β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 129:289-294 (1996).
Handbook of Chemistry and Physics, 67th Edition, CRCPress, Boca Raton, 1986-1987.
S. Takenouchi and G. C. Kennedy. The binary system H2O-CO2 at high temperatures and pressures. Am. J. Sci. 262:1055-1074 (1964).
P. Debenedetti, J. Tom, S-D Y, and G-B Lim. Application of supercritical fluids for the production of sustained delivery devices. J. Contr. Rel. 24:27-44 (1993).
